Immuneering (IMRX) Change in Account Payables (2020 - 2026)
Immuneering (IMRX) posted quarterly Change in Account Payables of -$89579.0 for Q1 2026, up 86.98% year-over-year from -$47909.0 in Q1 2025, and down 222.02% quarter-over-quarter from $73415.0 in Q4 2025.
Powered by 
Analysis
Immuneering (IMRX) Change in Account Payables (2020 - 2026) Analysis & Trends
Immuneering's Change in Account Payables history runs 7 years deep, the most recent figure standing at -$89579.0 for Q1 2026.
- In Q1 2026, Change in Account Payables rose 86.98% year-over-year to -$89579.0; the TTM figure through Mar 2026 stood at $197493.0 (up 121.53% YoY), while the FY2025 annual figure was -$400799.0, down 257.4% from the prior year.
- Change in Account Payables for Q1 2026 stood at -$89579.0, down from $73415.0 in the prior quarter.
- The five-year high for Change in Account Payables was $1.2 million in Q2 2025, with the low at -$974893.0 in Q3 2025.
- The 5-year median for Change in Account Payables is $56741.0 (2024), against an average of $2988.2.
- The sharpest annual moves came in 2022 and 2024: Change in Account Payables slumped 731.07% in 2022, then jumped 675.42% in 2024.
- Immuneering's Change in Account Payables stood at $816177.0 in 2022, then tumbled by 79.1% to $170568.0 in 2023, then slumped by 66.73% to $56741.0 in 2024, then rose by 29.39% to $73415.0 in 2025, then sank by 222.02% to -$89579.0 in 2026.
- Business Quant data shows IMRX's Change in Account Payables at -$89579.0 in Q1 2026, $73415.0 in Q4 2025, and -$974893.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -8.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 5.03 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 37.53 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Immuneering | 313.13 Mn | 313.13 Mn | - | 1.92 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.92 Mn |
| Mar 31, 2026 | -89,579.00 |
| Dec 31, 2025 | 73,415.00 |
| Sep 30, 2025 | -974,893.00 |
| Jun 30, 2025 | 1.19 Mn |
| Mar 31, 2025 | -687,871.00 |
| Dec 31, 2024 | 56,741.00 |
| Sep 30, 2024 | -679,454.00 |
| Jun 30, 2024 | 393,177.00 |
| Mar 31, 2024 | 117,393.00 |
| Dec 31, 2023 | 170,568.00 |
| Sep 30, 2023 | -778,202.00 |
| Jun 30, 2023 | -68,329.00 |
| Mar 31, 2023 | -430,933.00 |
| Dec 31, 2022 | 816,177.00 |
| Sep 30, 2022 | 1.10 Mn |
| Jun 30, 2022 | -402,121.00 |
| Mar 31, 2022 | 248,022.00 |
| Dec 31, 2021 | -445,014.00 |
| Sep 30, 2021 | 362,637.00 |